{"public_id":"co_519269fc761d2421222a10b7de7c3605","status":"active","merged_into_public_id":null,"resolved_public_id":"co_519269fc761d2421222a10b7de7c3605","name":"chimeric monoclonal antibody cA2","description":"A chimeric monoclonal antibody directed against tumor necrosis factor alpha and tested as a treatment for Crohn's disease.","aliases":["cA2"],"types":["drug","therapeutic antibody"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":75311601,"title":"A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease","citation_count":2888,"url":"https://sah.borca.ai/papers/75311601"}],"claims":[{"public_id":"cl_331fb42b16e2e061fa248eb89f0b7a42","text":"cA2 also yielded a higher remission rate than placebo at four weeks.","corpus_id":75311601,"url":"https://sah.borca.ai/claims/cl_331fb42b16e2e061fa248eb89f0b7a42"},{"public_id":"cl_465a97d2d0fc03170dfc7a2f2b972a0a","text":"A single intravenous infusion of cA2 produced substantially higher four-week clinical response rates than placebo in moderate-to-severe treatment-resistant Crohn's disease.","corpus_id":75311601,"url":"https://sah.borca.ai/claims/cl_465a97d2d0fc03170dfc7a2f2b972a0a"},{"public_id":"cl_c8a0c2b95de260ad48998a5042504663","text":"Clinical response persisted at 12 weeks in a larger proportion of cA2-treated patients than in the placebo group.","corpus_id":75311601,"url":"https://sah.borca.ai/claims/cl_c8a0c2b95de260ad48998a5042504663"},{"public_id":"cl_eb34dac5c835591d64574fc128493a4f","text":"Adverse-effect rates were similar between cA2 and placebo groups.","corpus_id":75311601,"url":"https://sah.borca.ai/claims/cl_eb34dac5c835591d64574fc128493a4f"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_519269fc761d2421222a10b7de7c3605","url":"https://sah.borca.ai/concepts/co_519269fc761d2421222a10b7de7c3605"}